title: Blocking PD-1 in Tumors with Faulty DNA Repair.
abstract: A phase II study shows that DNA mismatch repair deficiency can render tumors highly sensitive to the PD-1 inhibitor pembrolizumab. Patients with a range of solid tumors, including colorectal and endometrial cancers, with the deficiency responded well and durably to immune checkpoint blockade, with minimal toxicity.
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D053843:DNA Mismatch Repair; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C582435:pembrolizumab